-+ 0.00%
-+ 0.00%
-+ 0.00%

MEDICENNA REPORTS MORE THAN DOUBLING OF MEDIAN OVERALL SURVIVAL IN GLIOBLASTOMA PATIENTS WITH UNRESECTABLE RECURRENT IDH-WT TUMORS FOLLOWING ONE TREATMENT WITH BIZAXOFUSP VERSUS A MATCHED EXTERNAL CONTROL AT SNO 2026

Reuters·11/16/2026 12:00:01

Please log in to view news